Absci Corporation Announces Q4 and Full Year 2024 Results Release Date and Participation in Healthcare Forum
Curated by THEOUTPOST
On Wed, 5 Mar, 8:04 AM UTC
3 Sources
3 Sources
[1]
Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025 - Absci (NASDAQ:ABSI)
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation ABSI, a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2024 after market close on Tuesday, March 18, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event. About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube. Investor Contact Alex Khan VP, Finance & Investor Relations investors@absci.com Media Contact press@absci.com ABSIAbsci Corp$3.28-4.09%OverviewMarket News and Data brought to you by Benzinga APIs
[2]
Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025 By Investing.com
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2024 after market close on Tuesday, March 18, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event. About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
[3]
Absci to Participate in the KeyBanc Capital Markets Healthcare Forum - Absci (NASDAQ:ABSI)
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation ABSI, a data-first generative AI drug creation company, today announced the company will be participating in the upcoming virtual KeyBanc Capital Markets Healthcare Forum. Absci management is scheduled to participate in a fireside chat on Wednesday, March 19th at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company's investor relations website at: investors.absci.com. About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube. Investor Contact Alex Khan VP, Finance & Investor Relations investors@absci.com Media Contact press@absci.com ABSIAbsci Corp$3.41-0.29%OverviewMarket News and Data brought to you by Benzinga APIs
Share
Share
Copy Link
Absci, a generative AI drug creation company, sets date for Q4 and 2024 financial results release and announces participation in KeyBanc Capital Markets Healthcare Forum, showcasing its AI-driven approach to drug development.
Absci Corporation Announces Financial Results Release Date
Absci Corporation (NASDAQ: ABSI), a pioneering company in the field of AI-driven drug creation, has set the date for the release of its fourth quarter and full year 2024 financial and operating results. The company will disclose these updates after the market closes on Tuesday, March 18, 2025 1.
Following the release, Absci's management team will host a conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the company's business developments, financial performance, and future outlook. Interested parties can access the live audio webcast on the company's investor relations website at investors.absci.com 2.
Participation in KeyBanc Capital Markets Healthcare Forum
In addition to the financial results announcement, Absci has confirmed its participation in the upcoming virtual KeyBanc Capital Markets Healthcare Forum. The company's management is scheduled to engage in a fireside chat on Wednesday, March 19th at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) 3.
This participation provides an opportunity for Absci to showcase its innovative approach to drug development and discuss its position in the rapidly evolving field of AI-driven pharmaceuticals. Investors and interested parties can access a live and archived webcast of the fireside chat through Absci's investor relations website.
Absci's Innovative Approach to Drug Creation
Absci Corporation describes itself as a "data-first generative AI drug creation company" that combines artificial intelligence with scalable wet lab technologies. The company's unique selling proposition lies in its ability to create better biologics for patients at an accelerated pace 1.
At the core of Absci's operations is its Integrated Drug Creation™ platform, which aims to revolutionize the drug development process. This platform is designed to:
- Accelerate time to clinic
- Increase the probability of success
- Simultaneously optimize multiple drug characteristics
The company's approach allows for the screening of billions of cells per week, enabling a rapid transition from AI-designed candidates to wet lab-validated candidates in as little as six weeks 2.
Company Structure and Global Presence
Absci's operations span across multiple locations, reflecting its commitment to leveraging diverse talent and resources:
- Headquarters: Vancouver, Washington
- AI Research Lab: New York City
- Innovation Center: Zug, Switzerland
This strategic positioning allows Absci to tap into various pools of expertise and maintain a global perspective on drug development and AI innovation 3.
Reference
[2]
AMD Invests $20 Million in Absci to Accelerate AI-Driven Drug Discovery
AMD announces a $20 million investment and strategic partnership with Absci, an AI-powered drug discovery company, to enhance AI capabilities in pharmaceutical research using AMD's high-performance computing solutions.
8 Sources
8 Sources
OmniAb to Showcase AI-Powered Antibody Discovery Platform at Upcoming Investor Conferences
OmniAb, a biotech company specializing in AI-driven antibody discovery, announces its participation in two major investor conferences in November, highlighting its innovative Biological Intelligence platform.
2 Sources
2 Sources
ImmunoPrecise Antibodies Reschedules Q3 Fiscal 2025 Financial Results Amid AI-Powered Antibody Discovery Progress
ImmunoPrecise Antibodies Ltd., a leader in AI-powered antibody discovery, has rescheduled its Q3 Fiscal 2025 financial results release to March 28, 2025, allowing auditors more time for valuation reviews.
2 Sources
2 Sources
ImmunoPrecise Antibodies Reschedules Financial Results and Business Highlights Report
ImmunoPrecise Antibodies Ltd. announces the rescheduling of its financial results and recent business highlights report for the fourth quarter and fiscal year-end 2024. The company cites the need for additional time to complete its year-end audit procedures.
2 Sources
2 Sources
Astera Labs Schedules Q4 2024 Financial Results Conference Call
Astera Labs, a leader in AI and cloud infrastructure connectivity solutions, announces its Q4 2024 financial results conference call for February 10, 2025.
2 Sources
2 Sources
Your one-stop AI hub
The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
The Outpost
Keep in touch
© 2025 TheOutpost.AI All rights reserved